For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1
Be confident your patients have received their dose with HCP-administered LEQVIO—the only twice-yearly* LDL-C lowering therapy.1
Are your patients ready to start LEQVIO? Find coverage in your area and fill out the Patient Start Form to begin.
*After 2 initial doses and taken with statin therapy.
†An event is defined as acute coronary syndrome (unstable angina, STEMl, or NSTEMI). Patients were screened within 5 weeks from their coronary event.2
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; PCSK9, proprotein convertase subtilisin/kexin type 9.
HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; PCSK9, proprotein convertase subtilisin/kexin type 9.